DXR — what changed in the latest 10-K
A section-by-section comparison of DXR's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-K · 2012-03-28 vs the prior 10-K · 2011-03-29
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| Business | Text added/removed | +39 | −13 | ~95 | 104 |
| Risk factors | Text added/removed | +1 | −19 | ~8 | 10 |
| MD&A | Text added/removed | +66 | −36 | ~24 | 50 |
| Market risk (Item 7A) | Text added/removed | +11 | −3 | ~3 | 12 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
Business
Text added vs the prior filing · source: 10-K · 2012-03-28
In 2005 and 2007, the Company and Dr. Joseph Feldschuh, its President and Chief Executive Officer, respectively, received Wells Notices from the Securities and Exchange Commission (“SEC”) requesting their comments on the SEC Staff’s view that the Company was in violation of Section 7(a) of the Inves…
In November 2009, the staff of the Northeast Regional Office of the SEC contacted the Company and invited both the Company and Dr. Feldschuh to make a new Wells submission based upon more recent operations and results. The Company and Dr. Feldschuh responded to the staff’s invitation on December 20,…
The Company disclosed in its Form 10-Q for September 30, 2010, Form 10-K for December 31, 2010 and Form 10-Q’s for March 31, 2011, June 30, 2011 and September 30, 2011 that the SEC instituted administrative proceedings pursuant to the Investment Company Act of 1940 on September 17, 2010. The New Yor…
The Company has disclosed in previous public filings that it is dependent upon earnings from its investment portfolio to fund operations and that a single individual, Dr. Joseph Feldschuh, makes all investment decisions.
The administrative proceeding took place from March 7, 2011 through March 9, 2011 in New York City. The Company feels strongly that the extensive documentation of its history of operations presented at the administrative proceeding demonstrated that it is primarily an operating medical instrumentati…
Text removed vs the prior filing · source: 10-K · 2011-03-29
Saltzberg, MT. Blood Volume Analysis Coupled with Ultrafiltration in the Management of Congestive Heart Failure – Guided Therapy to Achieve Euvolemia. US Cardiology. 2010: 7:72-75.
The Company has also trademarked its Blood Optimization Program™ (BOP) for maximizing blood safety during surgery. The BOP uses a combination of blood volume measurement, pre-surgical treatment of blood volume deficits, and frozen autologous blood transfusion to maximize patient outcomes following s…
In 2005 the Company hired an individual with marketing experience to promote the Blood Optimization Program (BOP). This program is intended to incorporate Daxor’s BVA-100 Blood Volume Analyzer and its subsidiary’s frozen autologous blood banking, with the goal of increasing awareness and utilization…
By 2002, the Company recognized that it needed to recruit an experienced medical device marketing staff. In September 2002 the Company hired a National Sales Manager and three Regional Sales Managers with extensive experience in the medical device and nuclear medicine field. Subsequently, several di…
The marketing team has made great progress in identifying which facilities and departments are most able to utilize the BVA-100 in a cost-effective manner and has developed a repertoire of educational and marketing material. Depending on a facility’s needs and its ability to perform studies that are…
Risk factors
Text added vs the prior filing · source: 10-K · 2012-03-28
Our patents for the BVA 100 expired in 2010.The Company filed two additional patent applications for an automated instrument to measure human blood volume in March of 2012. The filings describe innovations which will be incorporated into the Company’s BVA-100 Blood Volume Analyzer. These application…
Text removed vs the prior filing · source: 10-K · 2011-03-29
In 2005 and 2007, the Company and Dr. Joseph Feldschuh, its President and Chief Executive Officer, respectively, received Wells Notices from the Securities and Exchange Commission (“SEC”) requesting their comments on the SEC Staff’s view that the Company was in violation of Section 7(a) of the Inves…
In November 2009, the staff of the Northeast Regional Office of the SEC contacted the Company and invited both the Company and Dr. Feldschuh to make a new Wells submission based upon more recent operations and results. The Company and Dr. Feldschuh responded to the staff’s invitation on December 20,…
The Company disclosed in its Form 10-Q for September 30, 2010 that the SEC instituted administrative proceedings pursuant to the Investment Company Act of 1940 on September 17, 2010. The New York City staff of the Enforcement Division of the SEC is claiming that Daxor is primarily an investment comp…
The Company has disclosed in previous public filings that it is dependent upon earnings from its investment portfolio to fund operations and that a single individual, Dr. Joseph Feldschuh, makes all investment decisions.
The administrative proceeding took place from March 7, 2011 through March 9, 2011 in New York City. The Company feels strongly that the extensive documentation of its history of operations presented at the administrative proceeding will demonstrate that it is primarily an operating medical instrumen…
MD&A
Text added vs the prior filing · source: 10-K · 2012-03-28
The study was part of a larger study (FAST Study) of 1,400 patients. The lead investigator was Dr. D.J. van Veldhuisen.The study, however, was prematurely terminated. The reason for the termination was that patients treated on the basis of the OptiVol® bio impedance monitor had a higher death rate. …
Revenue from service contracts on BVA-100 Blood Volume Ananlyzers and related maintenance services increased from $99,390 for the year ended December 31, 2010 to $102,865 for the year ended December 31, 2011.
The revenue from kit sales decreased by 5.1% for the year ended December 31, 2011 versus the same period in 2010. The number of kits sold decreased by 3.8% for the year ended December 31, 2011 versus the same period in 2010. For the year ended December 31, 2011, the Company sold 3,031 blood volume m…
The number of Blood Volume Analyzers placed into service was 61 at December 31, 2011 and 56 at December 31, 2010. The decrease in revenue from kit sales in 2011 versus 2010 can be attributed to a decrease in visits by patients with the type of conditions that would require blood volume measurement t…
The following tables provide gross margin information on Equipment Sales & Related Services for the years ended December 31, 2011 and December 31, 2010:
Text removed vs the prior filing · source: 10-K · 2011-03-29
The revenue from kit sales decreased by 10.4% for the year ended December 31, 2010 versus the same period in 2009. The number of kits sold decreased by 11.6% for the year ended December 31, 2010 versus the same period in 2009. For the year ended December 31, 2010, the Company sold 3,152 blood volume…
The number of Blood Volume Analyzers placed into service was 56 at December 31, 2010 and December 31, 2009. The decrease in revenue from kit sales in 2010 versus 2009 can be attributed to a decrease in visits by patients with the type of conditions that would require blood volume measurement to faci…
The following tables provide gross margin information on Equipment Sales & Related Services for the years ended December 31, 2010 and December 31, 2009:
The increase in Gross Profit Percentage on Kit Sales for the year ended December 31, 2010 versus 2009 is mostly due to two factors:
A small price increase on our Volumex Kits which was effective October 1, 2010. This was the first time the Company has increased prices on our Volumex kits since February 1, 2007.
Market risk (Item 7A)
Text added vs the prior filing · source: 10-K · 2012-03-28
Type of Security Total Fair Market Value Total Cost Total Net Unrealized Gain
Summary of Proceeds Received and Market Valuation at 12/31/11
Total Proceeds Received on open positions at 01/01/11 Sale of Options from 01/01/11-12/31/11 Expirations and Assignments of Options from 01/01/11-12/31/11 Proceeds Received on open positions at 12/31/11 Market Value at 12/31/11 Unrealized Loss at 12/31/11
Summary of Unrealized Losses on Available for Sale Securities
Fair Value Unrealized Loss Fair Value Unrealized Loss Fair Value Unrealized Loss
Text removed vs the prior filing · source: 10-K · 2011-03-29
Summary of Proceeds Received and Market Valuation at 12/31/09
Summary of Unrealized Losses on Available for Sale Securities
Summary of Unrealized Gains on Available for Sale Securities
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice